The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
A look at sector share prices in the opening three months of 2019 reveals a resurgent big pharma and a strong showing from the world’s other large drug makers, with US…
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Some medtech stocks did decline in 2018, but many more increased in value.
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?